[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with an acquired demyelinating sensorimotor neuropathy (indicated by conduction block, temporal dispersion, and cytoalbuminologic dissociation). MMN (A) is excluded by the presence of significant sensory deficits. Lupus-associated mononeuritis (C) is typically axonal, not demyelinating. HNPP (E) is unlikely due to the presence of temporal dispersion and the progressive (rather than episodic) course. The decision rests between CIDP (B) and Lewis-Sumner syndrome/MADSAM (D). The item is logically invalid due to a direct contradiction between the stem and the keyed answer's definition. The stem explicitly states the weakness is \\\"symmetric,\\\" which is the defining feature of CIDP. The keyed answer, Lewis-Sumner syndrome, is clinically defined as an *asymmetric* variant. The author's own rationale states that Lewis-Sumner is \\\"characterized by asymmetric... involvement... distinguishing it from CIDP (symmetric).\\\" Additionally, the stem references \\\"ulnar deep tendon reflexes,\\\" which is medically inaccurate terminology (no standard ulnar DTR exists). While the focal ulnar distribution favors MADSAM, the explicit \\\"symmetric\\\" descriptor makes the keyed answer indefensible against the distractor.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with an acquired demyelinating sensorimotor neuropathy (indicated by conduction block, temporal dispersion, and cytoalbuminologic dissociation). MMN (A) is excluded by the presence of significant sensory deficits. Lupus-associated mononeuritis (C) is typically axonal, not demyelinating. HNPP (E) is unlikely due to the presence of temporal dispersion and the progressive (rather than episodic) course. The decision rests between CIDP (B) and Lewis-Sumner syndrome/MADSAM (D). The item is logically invalid due to a direct contradiction between the stem and the keyed answer's definition. The stem explicitly states the weakness is \"symmetric,\" which is the defining feature of CIDP. The keyed answer, Lewis-Sumner syndrome, is clinically defined as an *asymmetric* variant. The author's own rationale states that Lewis-Sumner is \"characterized by asymmetric... involvement... distinguishing it from CIDP (symmetric).\" Additionally, the stem references \"ulnar deep tendon reflexes,\" which is medically inaccurate terminology (no standard ulnar DTR exists). While the focal ulnar distribution favors MADSAM, the explicit \"symmetric\" descriptor makes the keyed answer indefensible against the distractor.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with postpartum thrombotic microangiopathy (TMA) characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. The worsening clinical status despite delivery (which typically resolves HELLP/preeclampsia) and the ADAMTS13 activity of 58% (ruling out TTP, which requires <10%) strongly suggest complement-mediated TMA (atypical HUS). Eculizumab is the standard treatment for aHUS. Option B (Factor H mutation) confirms a genetic defect in the alternative complement pathway, providing the strongest mechanistic evidence for the diagnosis and the use of a terminal complement inhibitor. While genetic results may take time in practice, in the context of a board exam question asking for 'support,' the identification of the mutation is the definitive confirmation. Option D (Low C3) is consistent with aHUS but has poor sensitivity and specificity. Option C (Elevated sFlt-1) would support a diagnosis of preeclampsia/HELLP, arguing against primary aHUS. Options A and E suggest distinct pathologies (Evans syndrome, APS). The item is logically valid and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with postpartum thrombotic microangiopathy (TMA) characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. The worsening clinical status despite delivery (which typically resolves HELLP/preeclampsia) and the ADAMTS13 activity of 58% (ruling out TTP, which requires <10%) strongly suggest complement-mediated TMA (atypical HUS). Eculizumab is the standard treatment for aHUS. Option B (Factor H mutation) confirms a genetic defect in the alternative complement pathway, providing the strongest mechanistic evidence for the diagnosis and the use of a terminal complement inhibitor. While genetic results may take time in practice, in the context of a board exam question asking for 'support,' the identification of the mutation is the definitive confirmation. Option D (Low C3) is consistent with aHUS but has poor sensitivity and specificity. Option C (Elevated sFlt-1) would support a diagnosis of preeclampsia/HELLP, arguing against primary aHUS. Options A and E suggest distinct pathologies (Evans syndrome, APS). The item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question is a well-constructed, high-level board exam item testing the management of complications in Hypertrophic Cardiomyopathy (HCM). The clinical vignette presents a patient with obstructive HCM, severe LVOT gradient (85 mmHg), extensive fibrosis (LGE), and drug-refractory ventricular tachycardia (VT). The keyed answer, Surgical Myectomy (B), is the most appropriate intervention. Literature supports that myectomy reduces the burden of appropriate ICD shocks and arrhythmias in obstructive HCM by relieving hemodynamic wall stress and physically removing the arrhythmogenic substrate (scarred septum). Alcohol septal ablation (A) is incorrect because it creates a controlled infarction (scar), which can be pro-arrhythmic and is generally avoided in patients with existing high arrhythmia burden. Catheter ablation (C) has limited efficacy in HCM due to intramural substrates and does not address the hemodynamic obstruction. Amiodarone (D) is a reasonable pharmacologic adjunct but less definitive than surgical correction of the underlying obstruction in a candidate failing maximal beta-blocker/disopyramide therapy. Transplant (E) is premature. The item is logically valid and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question is a well-constructed, high-level board exam item testing the management of complications in Hypertrophic Cardiomyopathy (HCM). The clinical vignette presents a patient with obstructive HCM, severe LVOT gradient (85 mmHg), extensive fibrosis (LGE), and drug-refractory ventricular tachycardia (VT). The keyed answer, Surgical Myectomy (B), is the most appropriate intervention. Literature supports that myectomy reduces the burden of appropriate ICD shocks and arrhythmias in obstructive HCM by relieving hemodynamic wall stress and physically removing the arrhythmogenic substrate (scarred septum). Alcohol septal ablation (A) is incorrect because it creates a controlled infarction (scar), which can be pro-arrhythmic and is generally avoided in patients with existing high arrhythmia burden. Catheter ablation (C) has limited efficacy in HCM due to intramural substrates and does not address the hemodynamic obstruction. Amiodarone (D) is a reasonable pharmacologic adjunct but less definitive than surgical correction of the underlying obstruction in a candidate failing maximal beta-blocker/disopyramide therapy. Transplant (E) is premature. The item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nThe clinical vignette describes a patient with dermatomyositis and anti-MDA5 antibodies, a marker strongly associated with Rapidly Progressive Interstitial Lung Disease (RP-ILD). The patient exhibits signs of RP-ILD (progressive dyspnea, new ground-glass opacities, low DLCO) despite initial treatment. Current expert consensus and guidelines (particularly data originating from Japan where this phenotype is prevalent) strongly advocate for early, aggressive 'triple therapy' consisting of high-dose glucocorticoids, a calcineurin inhibitor (e.g., tacrolimus), and cyclophosphamide to improve survival in this high-mortality condition. \\n\\nOption B accurately reflects this standard of care. Option A (MMF) and Option C (Rituximab) are typically reserved for less acute cases or as second-line/rescue therapies, respectively, and are considered insufficient as primary stabilization for anti-MDA5 RP-ILD compared to the keyed regimen. Option D (Nintedanib) targets fibrosis, not the acute inflammation driving RP-ILD. The item is medically accurate, logically sound, and tests a specific, high-yield management principle in rheumatology/pulmonology.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nThe clinical vignette describes a patient with dermatomyositis and anti-MDA5 antibodies, a marker strongly associated with Rapidly Progressive Interstitial Lung Disease (RP-ILD). The patient exhibits signs of RP-ILD (progressive dyspnea, new ground-glass opacities, low DLCO) despite initial treatment. Current expert consensus and guidelines (particularly data originating from Japan where this phenotype is prevalent) strongly advocate for early, aggressive 'triple therapy' consisting of high-dose glucocorticoids, a calcineurin inhibitor (e.g., tacrolimus), and cyclophosphamide to improve survival in this high-mortality condition. \n\nOption B accurately reflects this standard of care. Option A (MMF) and Option C (Rituximab) are typically reserved for less acute cases or as second-line/rescue therapies, respectively, and are considered insufficient as primary stabilization for anti-MDA5 RP-ILD compared to the keyed regimen. Option D (Nintedanib) targets fibrosis, not the acute inflammation driving RP-ILD. The item is medically accurate, logically sound, and tests a specific, high-yield management principle in rheumatology/pulmonology.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item describes a patient with HIV-associated cryptococcal meningitis receiving standard induction therapy who presents with worsening signs of elevated intracranial pressure (ICP) (headache, CN VI palsy, OP 38 cm H2O) despite daily lumbar punctures. The key discriminating findings are the decreasing cryptococcal antigen titer (indicating microbiological response, arguing against treatment failure) and the persistently high ICP. The correct next step is to manage the life-threatening ICP more aggressively. Option D is the best answer; guidelines recommend increasing the frequency of LPs or placing a temporary lumbar drain if daily LPs are insufficient. Option A is incorrect because corticosteroids are contraindicated in cryptococcal meningitis (COAT trial) and true IRIS typically requires ART initiation. Option B is incorrect because the falling antigen titer suggests treatment efficacy. Option C is incorrect as a primary next step; permanent shunts (VPS) are reserved for cases refractory to temporary drains or frequent LPs, and placing permanent hardware during acute infection carries high risks. Option E is incorrect because ART should be delayed 4–6 weeks to prevent lethal IRIS. The question is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item describes a patient with HIV-associated cryptococcal meningitis receiving standard induction therapy who presents with worsening signs of elevated intracranial pressure (ICP) (headache, CN VI palsy, OP 38 cm H2O) despite daily lumbar punctures. The key discriminating findings are the decreasing cryptococcal antigen titer (indicating microbiological response, arguing against treatment failure) and the persistently high ICP. The correct next step is to manage the life-threatening ICP more aggressively. Option D is the best answer; guidelines recommend increasing the frequency of LPs or placing a temporary lumbar drain if daily LPs are insufficient. Option A is incorrect because corticosteroids are contraindicated in cryptococcal meningitis (COAT trial) and true IRIS typically requires ART initiation. Option B is incorrect because the falling antigen titer suggests treatment efficacy. Option C is incorrect as a primary next step; permanent shunts (VPS) are reserved for cases refractory to temporary drains or frequent LPs, and placing permanent hardware during acute infection carries high risks. Option E is incorrect because ART should be delayed 4–6 weeks to prevent lethal IRIS. The question is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette presents a classic case of Progressive Multifocal Leukoencephalopathy (PML) in a patient on immunosuppression (adalimumab/methotrexate), confirmed by JC virus PCR and non-enhancing white matter lesions. Following the discontinuation of the immunosuppressant, the patient develops worsening symptoms, new contrast enhancement, edema, and increased CSF pleocytosis. This clinical evolution is diagnostic of PML-IRIS (Immune Reconstitution Inflammatory Syndrome). The standard management for symptomatic PML-IRIS, especially with edema and neurological decline, is the initiation of corticosteroids to reduce the excessive inflammatory response. Therefore, the keyed answer (B) is correct. Restarting the original immunosuppressant (A) is generally not indicated. Cidofovir/cytarabine (C) have no proven efficacy. Pembrolizumab (D) is used to boost the immune response in patients failing to clear the virus, which is the opposite of what is needed in IRIS. Biopsy (E) is unnecessary given the molecular diagnosis. The item is logically valid and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette presents a classic case of Progressive Multifocal Leukoencephalopathy (PML) in a patient on immunosuppression (adalimumab/methotrexate), confirmed by JC virus PCR and non-enhancing white matter lesions. Following the discontinuation of the immunosuppressant, the patient develops worsening symptoms, new contrast enhancement, edema, and increased CSF pleocytosis. This clinical evolution is diagnostic of PML-IRIS (Immune Reconstitution Inflammatory Syndrome). The standard management for symptomatic PML-IRIS, especially with edema and neurological decline, is the initiation of corticosteroids to reduce the excessive inflammatory response. Therefore, the keyed answer (B) is correct. Restarting the original immunosuppressant (A) is generally not indicated. Cidofovir/cytarabine (C) have no proven efficacy. Pembrolizumab (D) is used to boost the immune response in patients failing to clear the virus, which is the opposite of what is needed in IRIS. Biopsy (E) is unnecessary given the molecular diagnosis. The item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with Behçet disease (oral/genital ulcers, uveitis, HLA-B51+) presenting with Central Retinal Artery Occlusion (CRAO) due to retinal vasculitis. The question specifically asks for the intervention to 'prevent contralateral involvement,' shifting the focus from acute salvage of the blind eye (which has a poor prognosis) to systemic disease control. Validity: Valid (V). The Key (D) is correct. Current guidelines (e.g., EULAR 2018) recommend anti-TNF agents (infliximab or adalimumab) combined with high-dose corticosteroids as the first-line therapy for severe, sight-threatening ocular Behçet disease (posterior uveitis/retinal vasculitis). Option A (steroids alone) is insufficient for long-term remission in severe cases. Option C (cyclosporine) is a traditional therapy but is now considered inferior to anti-TNFs for severe posterior segment disease and carries neurotoxicity risks. Option E (paracentesis) addresses embolic CRAO mechanics but does not treat the underlying vasculitis or protect the contralateral eye. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with Behçet disease (oral/genital ulcers, uveitis, HLA-B51+) presenting with Central Retinal Artery Occlusion (CRAO) due to retinal vasculitis. The question specifically asks for the intervention to 'prevent contralateral involvement,' shifting the focus from acute salvage of the blind eye (which has a poor prognosis) to systemic disease control. Validity: Valid (V). The Key (D) is correct. Current guidelines (e.g., EULAR 2018) recommend anti-TNF agents (infliximab or adalimumab) combined with high-dose corticosteroids as the first-line therapy for severe, sight-threatening ocular Behçet disease (posterior uveitis/retinal vasculitis). Option A (steroids alone) is insufficient for long-term remission in severe cases. Option C (cyclosporine) is a traditional therapy but is now considered inferior to anti-TNFs for severe posterior segment disease and carries neurotoxicity risks. Option E (paracentesis) addresses embolic CRAO mechanics but does not treat the underlying vasculitis or protect the contralateral eye. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with features of the AMAN variant of Guillain-Barré Syndrome (GBS), including anti-GM1 antibodies and axonal electrophysiology. However, the 6-week duration of progression is atypical for GBS (defined by progression <4 weeks) and raises the possibility of CIDP. The primary logical failure lies in the management options. The keyed answer, initiating plasma exchange (PLEX) after IVIG failure, is widely considered incorrect in modern practice because PLEX removes the recently administered immunoglobulins, negating the initial therapy. Major guidelines (e.g., AAN) advise against this sequence. The standard of care for GBS patients deteriorating after IVIG is supportive care. While a second course of IVIG (Option A) is sometimes considered (though evidence is weak), and steroids (Option C) would be correct if this were CIDP, the keyed answer promotes a mechanism (sequential PLEX after IVIG) that is theoretically counterproductive and guideline-non-compliant. Thus, no answer is defensible as 'best' among the choices provided.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with features of the AMAN variant of Guillain-Barré Syndrome (GBS), including anti-GM1 antibodies and axonal electrophysiology. However, the 6-week duration of progression is atypical for GBS (defined by progression <4 weeks) and raises the possibility of CIDP. The primary logical failure lies in the management options. The keyed answer, initiating plasma exchange (PLEX) after IVIG failure, is widely considered incorrect in modern practice because PLEX removes the recently administered immunoglobulins, negating the initial therapy. Major guidelines (e.g., AAN) advise against this sequence. The standard of care for GBS patients deteriorating after IVIG is supportive care. While a second course of IVIG (Option A) is sometimes considered (though evidence is weak), and steroids (Option C) would be correct if this were CIDP, the keyed answer promotes a mechanism (sequential PLEX after IVIG) that is theoretically counterproductive and guideline-non-compliant. Thus, no answer is defensible as 'best' among the choices provided.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid)\\nVerdict on keyed answer: Correct best\\n\\nThe item presents a classic decision-making scenario for acute ischemic stroke management. The patient has a Large Vessel Occlusion (LVO) of the left M1 segment and salvageable brain tissue (large penumbra), making her a candidate for reperfusion. However, she is on warfarin with an INR of 2.8. According to AHA/ASA guidelines, IV alteplase is contraindicated in patients with an INR > 1.7. Therefore, Option A is incorrect. Reversing anticoagulation to administer tPA (Option C) is not recommended as it delays the definitive treatment (thrombectomy) and lacks evidence compared to direct intervention. Option D is incorrect because idarucizumab reverses dabigatran, not warfarin. Option E is incorrect because the patient is a candidate for intervention. Direct Endovascular Thrombectomy (EVT) without prior thrombolysis (Option B) is the standard of care for patients with LVO who are ineligible for IV tPA. The question is medically accurate, logically sound, and the key is uniquely defensible.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid)\nVerdict on keyed answer: Correct best\n\nThe item presents a classic decision-making scenario for acute ischemic stroke management. The patient has a Large Vessel Occlusion (LVO) of the left M1 segment and salvageable brain tissue (large penumbra), making her a candidate for reperfusion. However, she is on warfarin with an INR of 2.8. According to AHA/ASA guidelines, IV alteplase is contraindicated in patients with an INR > 1.7. Therefore, Option A is incorrect. Reversing anticoagulation to administer tPA (Option C) is not recommended as it delays the definitive treatment (thrombectomy) and lacks evidence compared to direct intervention. Option D is incorrect because idarucizumab reverses dabigatran, not warfarin. Option E is incorrect because the patient is a candidate for intervention. Direct Endovascular Thrombectomy (EVT) without prior thrombolysis (Option B) is the standard of care for patients with LVO who are ineligible for IV tPA. The question is medically accurate, logically sound, and the key is uniquely defensible.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: N (No answer defensible). Verdict: No defensible answer. The question asks to identify the factor that most strongly predicts the patient's likelihood of complete LV recovery. The keyed answer (A) relies on the 'Absence of late gadolinium enhancement,' but the vignette never reports cardiac MRI results, making this option purely speculative (Underspecified). Furthermore, the patient has a confirmed TTN truncating variant (Option C) and a baseline LVEF of 25%. Current consensus (e.g., IPAC study) identifies baseline LVEF <30% and TTN variants as the strongest predictors of incomplete recovery. Therefore, Option C is the strongest actual predictor present in the vignette (predicting a low likelihood of recovery), while Option D (LVEF >30%) is factually false for this patient. The keyed answer is medically inaccurate (baseline LVEF is consistently cited as a stronger predictor than LGE status in PPCM) and logically invalid because it requires selecting a finding not stated in the stem over a confirmed genetic finding that strongly drives prognosis.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: N (No answer defensible). Verdict: No defensible answer. The question asks to identify the factor that most strongly predicts the patient's likelihood of complete LV recovery. The keyed answer (A) relies on the 'Absence of late gadolinium enhancement,' but the vignette never reports cardiac MRI results, making this option purely speculative (Underspecified). Furthermore, the patient has a confirmed TTN truncating variant (Option C) and a baseline LVEF of 25%. Current consensus (e.g., IPAC study) identifies baseline LVEF <30% and TTN variants as the strongest predictors of incomplete recovery. Therefore, Option C is the strongest actual predictor present in the vignette (predicting a low likelihood of recovery), while Option D (LVEF >30%) is factually false for this patient. The keyed answer is medically inaccurate (baseline LVEF is consistently cited as a stronger predictor than LGE status in PPCM) and logically invalid because it requires selecting a finding not stated in the stem over a confirmed genetic finding that strongly drives prognosis.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}]